×
Vaxxinity EBIT 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Vaxxinity ebit from 2020 to 2023. Ebit can be defined as earnings before interest and taxes.
View More
Vaxxinity EBIT 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Vaxxinity ebit from 2020 to 2023. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$139.4B
Bristol Myers Squibb (BMY)
$115.2B
Gilead Sciences (GILD)
$114.5B
Vertex Pharmaceuticals (VRTX)
$104.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$78.6B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$37.4B
Alnylam Pharmaceuticals (ALNY)
$30.1B
BioNTech SE (BNTX)
$27.6B
Biogen (BIIB)
$21.9B
Illumina (ILMN)
$20.8B
BeiGene (ONC)
$18B
Moderna (MRNA)
$16.2B
Genmab (GMAB)
$13.9B
Incyte (INCY)
$13.4B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.5B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.4B
Exact Sciences (EXAS)
$10.5B
Vaxcyte (PCVX)
$10.4B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8B